<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376154</url>
  </required_header>
  <id_info>
    <org_study_id>112335</org_study_id>
    <nct_id>NCT01376154</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)</brief_title>
  <official_title>Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm efficacy and safety when administering lamivudine
      tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events in Japanese subjects with hepatitis B virus-induced liver cirrhosis treated with lamivudine tablet</measure>
    <time_frame>6 months or more</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">342</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Subjects prescribed lamivudine tablet</arm_group_label>
    <description>Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <arm_group_label>Subjects prescribed lamivudine tablet</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japanese subjects with hepatitis B virus-induced liver cirrhosis, in whom lamivudine tablet
        was administered alone for 6 months or longer, or those in whom lamivudine tablet was
        expected to be administered alone for 6 months or longer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with hepatitis B virus-induced liver cirrhosis, in whom lamivudine tablet was
             administered alone for 6 months or longer, or those in whom lamivudine tablet was
             expected to be administered alone for 6 months or longer

        Exclusion Criteria:

          -  Subjects previously enrolled in Drug Use Investigation or Special Drug Use
             Investigation of lamivudine tablet

          -  Subjects with a history of hypersensitivity of the ingredients of lamivudine tablet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

